

CARE Checklist of information to include when writing a case report



| Торіс | Item No | Checklist item description | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|----------------------------------|------------|--|---|----------------------------------|
| Title | 1 | The diagnosis or intervention of primary focus followed by the words "case report" | Page 1/Line 2 | Title/Paragraph 1 |
| Key Words | 2 | 2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" | Page 1/Line 21 | Keywords/Paragraph 1 |
| Abstract (Structured summary) | 3a | Background: state what is known and unknown; why the case report is unique and what it adds to existing literature. | Page 3/Line 47-53 | Abstract/Paragraph 1 |
| | 3b | Case Description: describe the patient's demographic details, main symptoms, history, important clinical findings, the main diagnosis, interventions, outcomes and follow-ups. | Page 3/Line 55-64 | Abstract/Paragraph 2 |
| | 3c | Conclusion: summarize the main take-away lesson, clinical impact and potential implications. | Page 4/Line 67-71 | Abstract/Paragraph 3 |
| Introduction | 4 | One or two paragraphs summarizing why this case is unique (may include references) | Page 5/Line 83-85 | Introduction/Paragraph 1 |
| Patient Information | 5a | De-identified patient specific information | Page 5/Line 87 | CP/Paragraph 1 |
| | 5b | Primary concerns and symptoms of the patient | Page 5/Line 89 | CP/Paragraph 1 |
| | 5c | Medical, family, and psycho-social history including relevant genetic information | NA | NA |
| | 5d | Relevant past interventions with outcomes | NA | NA |
| Clinical Findings | 6 | Describe significant physical examination (PE) and important clinical findings | Page 5/Line 92 | CP/Paragraph 1 |
| Timeline | 7 | Historical and current information from this episode of care organized as a timeline | NA | NA |
| Diagnostic Assessment | 8a | Diagnostic testing (such as PE, laboratory testing, imaging, surveys). | Page 5/Line 92 | CP/Paragraph 1 |
| | 8b | Diagnostic challenges (such as access to testing, financial, or cultural) | NA | NA |
| | 8c | Diagnosis (including other diagnoses considered) | Page 5/Line 91 | CP/Paragraph 1 |
| | 8d | Prognosis (such as staging in oncology) where applicable | Page 5/Line 91-92 | CP/Paragraph 1 |
| Therapeutic Intervention | 9a | Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) | Page 6/Line 103-104 | CP/Paragraph 3 |
| | 9b | Administration of therapeutic intervention (such as dosage, strength, duration) | Page 6/Line 103 | CP/Paragraph 3 |
| | 9c | Changes in therapeutic intervention (with rationale) | NA | NA |
| | | , | | |

| Follow-up and Outcomes | 10a | Clinician and patient-assessed outcomes (if available) | Page 6 / Line 107 - 111 | CP/Paragraph 3 |
|---------------------------|-----|--|-------------------------|------------------------|
| | 10b | Important follow-up diagnostic and other test results | Page 7/ Line 110 - 111 | CP/Paragraph 3 |
| | 10c | Intervention adherence and tolerability (How was this assessed?) | NA | NA |
| | 10d | Adverse and unanticipated events | Page 7 /Line 111 | CP/Paragraph 3 |
| Discussion | 11a | A scientific discussion of the strengths AND limitations associated with this case report | Page 11 / Line 143-147 | Discussion/Paragraph 1 |
| | 11b | Discussion of the relevant medical literature with references | Page 11 / Line 155-170 | Discussion/Paragraph 3 |
| | 11c | The scientific rationale for any conclusions (including assessment of possible causes) | Page 12 / Line 172-182 | Discussion/Paragraph 4 |
| | 11d | The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion | Page 12 / Line 184-192 | Discussion/Paragraph 5 |
| Patient Perspective | 12 | The patient should share their perspective in one to two paragraphs on the treatment(s) they received | NA | NA |
| Informed Consent | 13 | Did the patient give informed consent? Please provide if requested | Yes | No 🔾 |

Article Information: https://dx.doi.org/10.21037/tlcr-23-788

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.